University of Nottingham spin-out company, Oncimmune, which specialises in the early detection of lung cancer, floated on AIM, a market operated by London Stock Exchange plc on 18 May 2016. (Read more about the IPO.)
Oncimmune was founded in 2003 by Professor John Robertson, Professor of Surgery at the School of Medicine based on his original idea in the field of autoantibodies for early cancer detection in 1995. He was a director of the company and Chief Scientific Officer from 2003 to 2013.
Prof Robertson said he was "very pleased to see all the previous work now coming to fruition."
Since leaving Oncimmune in 2013, he has continued his work in early cancer detection. His team is developing a similar test for colon cancer funded by a grant from the Medical Research Council, as well as an early detection test for breast cancer supported by the University's Life Cycle 6 campaign.
Support Life Cycle 6 - Stop Breast Cycle.
The University of Nottingham Royal Derby Hospital Uttoxeter Road, Derby, DE22 3DT
telephone: +44 (0) 1332 724622 email:gem@nottingham.ac.uk